SynthesisExpert review of gastroenterology & hepatology2016
Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.
Synthesis in Expert review of gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 110 citations in OpenAlex.
- Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects.Clinical drug investigation · 2019Trial
- The JAK1 Inhibitor Upadacitinib Curbs Acute Liver Failure via Suppressing IFN-γ/JAK1/STAT1 and TNF-α/NF-κB/MAPK Pathways and Modulating Bax/Bcl-2 Ratio.Journal of xenobiotics · 2026Article
- [Differences in the mechanisms, diagnostic biomarkers, and therapeutic strategies of drug-induced liver injury caused by traditional Chinese and Western medicines].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
- Common Adverse Reactions and Management Strategies of First-Line Anti-Tuberculosis Drugs.Infection and drug resistance · 2026Review
- The Hepatoprotective Properties of the Revised Formulation of Dahuang Xiaoshi Tang, an Ancient Chinese Herbal Decoction, Are Probed by Integrated Metabolomics and Network Pharmacology.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Enabling Drug-Induced Liver Injury Surveillance Through Automated Medication Extraction From Clinical Notes: A Medical Information Mart for Intensive Care IV Real-World Large Language Models Validation Study.Gastroenterology research · 2025Article
- Improvement effect of Biluochun tea active extract on CClFood science and biotechnology · 2025Article
- Insights into medication-induced liver injury: Understanding and management strategies.Toxicology reports · 2025Review
- Drug-Induced Liver Injury: Mechanisms, Diagnosis, and Management: A Review.Journal of pharmacy & bioallied sciences · 2025Review
- Drug-induced liver injury due to avacopan improved by mycophenolate mofetil: A case report.Medicine · 2025Article
- Drug-induced liver injury. Part I: Classification, diagnosis and treatment.Clinical and experimental hepatology · 2025Review
- Drug-Induced Liver Injury-Pharmacological Spectrum Among Children.International journal of molecular sciences · 2025Review
- Bactrim-Induced Hepatotoxicity.Cureus · 2024Article
- Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review.Molecular biology reports · 2024Review
- Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction.Cellular and molecular life sciences : CMLS · 2024Review
- Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use.Drug safety · 2024Review
- Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms.World journal of hepatology · 2023Review
- Article
- Liver Protection of a Low-Polarity Fraction fromMolecules (Basel, Switzerland) · 2023Article
- Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments.World journal of gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
While the pace of discovery of new agents, mechanisms and risk factors involved in drug-induced liver injury (DILI) remains brisk, advances in the treatment of acute DILI seems slow by comparison. In general, the key to treating suspected DILI is to stop using the drug prior to developing irreversible liver failure. However, predicting when to stop is an inexact science, and commonly used ALT monitoring is an ineffective strategy outside of clinical trials. The only specific antidote for acute DILI remains N-acetylcysteine (NAC) for acetaminophen poisoning, although NAC is proving to be beneficial in some cases of non-acetaminophen DILI in adults. Corticosteroids can be effective for DILI associated with autoimmune or systemic hypersensitivity features. Ursodeoxycholic acid, silymarin and glycyrrhizin have been used to treat DILI for decades, but success remains anecdotal. Bile acid washout regimens using cholestyramine appear to be more evidenced based, in particular for leflunomide toxicity. For drug-induced acute liver failure, the use of liver support systems is still investigational in the United States and emergency liver transplant remains limited by its availability. Primary prevention appears to be the key to avoiding DILI and the need for acute treatment. Pharmacogenomics, including human leukocyte antigen genotyping and the discovery of specific DILI biomarkers offers significant promise for the future. This article describes and summarizes the numerous and diverse treatment and prevention modalities that are currently available to manage DILI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.